



Universiteit
Leiden
The Netherlands

Improving management of infectious diseases at the emergency department: from risk prediction to treatment strategies

Kaal, A.G.

Citation


Kaal, A. G. (2026, September 16). *Improving management of infectious diseases at the emergency department: from risk prediction to treatment strategies*. Retrieved from <https://hdl.handle.net/1887/4309760>


Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4309760>

Note: To cite this publication please use the final published version (if applicable).



The background is an abstract composition of warm, vibrant colors including shades of yellow, orange, red, and magenta. The colors are blended together with visible, expressive brushstrokes, creating a sense of movement and depth. The overall effect is a rich, textured surface that serves as a backdrop for the text.

Part I

Diagnostics: Improving the diagnostic process
of bacteremia using procalcitonin



Chapter 2

The diagnostic accuracy of procalcitonin for community-acquired bacteraemia: an updated systematic review and meta-analysis

Anna G. Kaal, Margot Nieberg, Koen Stegmeijer, Ewout W. Steyerberg, Cees van Nieuwkoop

ABSTRACT

Background

Procalcitonin is known to have moderate diagnostic accuracy for bacteremia. A 2014 meta-analysis showed 76% sensitivity for a 0.50 ng/mL threshold. Lower thresholds might improve sensitivity.

Objectives

To determine the diagnostic accuracy of procalcitonin for community-acquired bacteraemia by conducting a systematic review and meta-analysis, focusing on the ability to exclude bacteraemia.

Methods

Data sources: We searched PUBMED, EMBASE and Web of Science from 1 January 2014 to 20 May 2025.

Study eligibility criteria and participants

Articles studying diagnostic accuracy of procalcitonin for community-acquired bacteraemia in adults.

Test and reference standard

Procalcitonin was compared with blood culture results.

Assessment of risk of bias

Risk of bias was assessed using the QUADAS-2 tool.

Methods of data synthesis

We pooled sensitivity/specificity with a bivariate random-effects model and created a summary receiver-operating curve. The main analysis focused on studies reporting on a procalcitonin threshold of 0.10 ng/mL. In addition, we analysed results for all studies, studies with a 0.25 ng/mL and studies with a 0.50 ng/mL threshold.

Results

We included 40 of 5450 identified articles, reflecting 192 529 patients of whom 31 480 (16%) had bacteraemia. Of 40 studies, 32 had high risk of bias. The pooled sensitivity for a 0.10 ng/mL threshold was 93% (95% CI: 85-97%) with a specificity of 36% (95% CI: 26-47%). The area under the summary receiver-operating curve for all studies was 0.80 (95% CI: 0.76-0.83%; prediction interval 0.57-0.91).

Discussion

A low cut-off value of procalcitonin can be useful to exclude community-acquired bacteraemia, depending on what the treating clinician considers to be an acceptable trade-off between sensitivity and specificity. Procalcitonin may require combination with clinical characteristics for accurate assessment of the risk of bacteraemia and safely reducing unnecessary blood cultures.

INTRODUCTION

Community-acquired bacteraemia (CAB) continues to lead to high morbidity and mortality if not treated timely and adequately.¹ Recognizing bacteraemia can be difficult because patients' symptoms are unspecific and most commonly used diagnostic tools either lack accuracy or do not lead to timely results to be used at an emergency department (ED). The fear of missing bacteraemia leads to overuse of diagnostic tests. Currently, the reference standard is blood cultures.² These only yield a true positive result in 4-11% of all blood cultures taken at the ED, whereas another 2-8% is contaminated with skin flora, and performing blood cultures is costly.³⁻⁸ It would therefore be of great value to find a way to improve the diagnostic process for bacteraemia. Because most patients with suspected infection or sepsis at ED do not have bacteraemia, finding a way to immediately rule out bacteraemia would help avoid unnecessary blood cultures and negative consequences of false-positive results.⁶⁻⁸ This is also in line with the increasing call for diagnostic stewardship aiming to minimize inappropriate diagnostic microbiology testing.^{9,10}

Procalcitonin (PCT), a biomarker with growing relevance to identify bacterial infections, has been extensively researched to identify bacteraemia.¹¹⁻¹⁵ A systematic review and meta-analysis from 2007 concluded that PCT had a moderate performance for diagnosing bacteraemia with an area under the curve (AUC) value of 0.84, a pooled sensitivity of 76% (95% CI: 66-84%) and a pooled specificity of 70% (95% CI: 60-79%).¹¹ In 2015, Hoeboer et al.¹² conducted a meta-analysis that concluded that PCT had a fair diagnostic accuracy for bacteraemia with an AUC of 0.78, a pooled sensitivity of 76% (95% CI: 69-82%) and a pooled specificity of 69% (95% CI: 64-72%) in the ED population. Both meta-analyses used cut-offs closest to 0.5 ng/mL in their analysis, whereas especially low values of PCT (<0.10 ng/mL, <0.25 ng/mL) are reported to have high sensitivities.¹²⁻¹⁴

Since this last review, multiple studies have been published that evaluate the diagnostic accuracy of PCT for bacteraemia using lower thresholds. This could lead to a better understanding of the usability of PCT to safely withhold blood cultures. Therefore, we aim to provide an up-to-date overview of the diagnostic accuracy of PCT for bacteraemia in adult patients presenting to the hospital with suspected infection, with a particular focus on its ability to exclude CAB, by performing a systematic review and meta-analysis.

METHODS

Search strategy and study selection

A search strategy was set up in collaboration with an information specialist (PG), see the supplementary material. The search strategy was built on a combination of terms for PCT, bacteraemia and diagnostic properties. We searched PUBMED, EMBASE and Web of Science from 1 January 2014 to 20 May 2025. We used Rayyan to identify potential duplicates. This programme estimates the probability that an article is included in duplicate. We deleted articles with a certainty over 95%. Studies were screened by title and abstract by a minimum of two individual researchers (AGK, MN, KS, CvN), and final inclusion was done after full-text review. Any disagreement was resolved through discussion. Finally, the reference lists of included articles were searched for additional relevant articles.

We included studies that studied solely adult patients ≥ 18 years suspected of having an infection. Articles were eligible for inclusion if they compared the diagnostic accuracy for CAB for PCT compared with the reference standard: blood cultures. They had to report diagnostic properties needed to create a 2×2 table of PCT versus blood culture results. CAB had to be defined as growth of a bacterial pathogen from a blood culture, taken at ED and/or within 48 hours of hospital admission. PCT had to be tested within 24 hours of blood culture withdrawal. Finally, a minimum of one cut-off value for PCT had to be defined. We included possible articles from all languages, using the translation app DeepL for languages other than English, Dutch or Spanish. Exclusion criteria were animal studies, case report or case-control studies, studies studying catheter related bacteraemia, studies that included common skin contaminants in their definition for positive blood culture or studies in burn patients. For studies that seemed eligible but did not report all necessary information, we contacted the corresponding author per e-mail to request additional information. Authors of studies that only reported on part of the cut-offs of interest were also asked to provide additional results. This study is reported according to the preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA) standards.¹⁶

Study protocol

We registered the study protocol at Prospero, with registration number CRD42023426791.

Data collection

We used a predefined data collection form (see supplementary material) for data collection. All information was collected in duplicate. Any disagreement was resolved by discussion, and in case of persistent disagreement, one of the other authors was consulted. We collected data regarding study characteristics (study design, country, and study year), specific information regarding the patient population such as reported use of immunosuppressants or recent antibiotics, whether there was a clear definition of false-positive blood cultures and the method used to analyse PCT.

Quality assessment

We used the QUADAS-2 tool to evaluate risk of bias and concerns regarding applicability.¹⁷ All evaluations were done in duplicate, with discrepancies resolved by discussion.

Statistical analysis

Because we aim to analyse the ability of low PCT values to exclude bacteraemia, our main analysis focused on the results reported for a PCT threshold of 0.10 ng/mL, including lower thresholds and up to 0.15 ng/mL. In addition, we analysed results for (1) thresholds of 0.25 ng/mL (including 0.15 ng/mL up to 0.35 ng/mL), (2) the more commonly suggested threshold of 0.50 ng/mL, including thresholds from 0.35 up to 0.65 ng/mL and (3) using the results of one PCT cut-off closest to 0.5 ng/mL for all included studies. For each analysis, only one cut-off per study was included.

We used the bivariate random-effects regression model to pool sensitivity and specificity. This was also used to create a summary receiver-operating curve for all included studies, using the results of the reported threshold closest to 0.5 ng/mL for comparability with previous studies. We included a prediction region to reflect the estimated sensitivity and specificity for a new study, taking between-study heterogeneity into account. We do not report quantitative measures of heterogeneity because these are not routinely used in DTA reviews because they do not account for heterogeneity explained by phenomena such as different positivity thresholds between studies.¹⁸ Heterogeneity can be visually inspected by the degree to which the observed study results lie close to the summary ROC curve. We estimated the prediction interval for the AUC of the ROC curve by running a random-effect meta-analysis with the 'metafor' package on all studies that reported the AUC with CI, estimating the results on a logit scale.¹⁹ In addition, we explored the influence of study and patient characteristics by performing multiple subanalyses in selected subgroups: prospective versus retrospective studies, according to setting (ED, ward, intensive care unit, or mix), studies with a clear definition of false-positive blood

cultures versus those without, studies including immunocompromised patients versus studies with immunocompetent patients only, according to whether studies included patients with recent use of antibiotics and, finally, according to specific site of infection. We used Deeks' funnel plot asymmetry test to evaluate publication bias, using the commonly used p value of <0.10 for the slope coefficient as a sign of significant asymmetry, indicating potential publication bias.¹⁸ A sensitivity analysis was done by calculating the summary estimates for low and high risk of bias studies and low level of concern and high level of concern for applicability as assessed by the QUADAS-2 criteria. Unclear risk was reclassified as high risk for this comparison. All analyses were conducted using Rstudio version 2024.09.0.

RESULTS

Study selection

Our literature search retrieved 5450 unique articles, of which 5255 were excluded after screening of title and abstract. A total of 191 full-text articles were screened for eligibility, of which 151 were excluded. Reasons for exclusion are depicted in Fig. 1; 31 were excluded because of multiple reasons that are separately listed in the supplementary material. Finally, a total of 40 cohort studies were included (Fig. 1, Table 1) accounting 192 529 patients of whom 31 480 (16.3%) had bacteraemia. The reported PCT cut-offs ranged from 0.10 to 10.83 ng/mL. All studies used automatized PCT assays (see supplementary material).

Risk of bias and applicability

We evaluated all studies using the QUADAS-2 tool (Table 2). Overall, 32 of 40 studies had a high risk of bias on at least one domain. An important source of bias was the unclear handling of contaminated blood cultures, by either not using a clear definition or unclear handling of the contaminated cultures in the analysis. We found less applicability concerns, only in 9 of 40 studies, which were mostly caused by the selection of a very specific population.




Figure 1. Flowchart of identification of new studies

Table 1. Characteristics of all included studies.

Study	Country	Type	Inclusion criteria	Setting (n)	Patients Age (y)	Male (%)	True positive BCs (%)	Contamination	Infection	Immuno-compromised	Antibiotic treatment	Cut-off values (ng/mL)
Aziji et al., 2022 ²⁰	Netherlands	Pro-spective	Suspected infection with performing of blood cultures and influenza PCR test	ED	546	64 (17)	301 (55)	47 (9)	Clear	Viral	Yes	Yes 0.1, 0.25, 0.5
Choe et al., 2016 ²¹	Korea	Retro-spective	Septic shock or severe sepsis with blood lactate ≥2.0 mmol/L	ED	1212	66 (55-74)	718 (59)	421 (35)	Unclear	Mixed	Yes	Unclear 0.25, 0.50
Ciotti et al., 2019 ²²	Italy	Pro-spective	Febrile outpatients with haematological malignancies	ED	70	Not specified	Not specified	11 (16)	Unclear	Mixed	Yes	Unclear 0.5
García de Guadiana-Romualdo et al., 2019 ²³	Spain	Pro-spective	Febrile neutropenia	ED	111	63 (21-85)	42 (38)	16 (14)	Clear	Mixed	Yes	Unclear 0.34
Julián-liménez et al., 2022 ²⁴	Spain	Pro-spective	Patients >65 y with clinically suspected infection	ED	2401	80 (8)	1489 (62)	579 (24)	Clear	Mixed	Unclear	Unclear 0.5
Harikrishna et al., 2020 ²⁵	India	Pro-spective	Acute fever	Mixed	450	51 (18)	312 (65)	44 (10)	Clear	Mixed	Unclear	Unclear 0.5
Hertz et al., 2024 ²⁶	Denmark	Pro-spective	Suspected urogenital tract infection	ED	173	75 (17)	102 (59)	39 (23)	Clear	Urogenital	Unclear	Unclear 0.15
Hoenigl et al., 2014 ²⁷	Austria	Pro-spective	Positive SIRS criteria	Mixed	515	BC-: 68, BC+: 66a	519 (58)a	282 (55)	Clear	Mixed	Unclear	No 0.1, 0.25, 0.5

Study	Country	Type	Inclusion criteria	Setting	Patients (n)	Age (y)	Male (%)	True positive BCs (%)	Contamination	Infection	Immuno-compromised treatment	Antibiotic Cut-off values (ng/mL)
Inoue et al., 2020 ²⁸	Japan	Unclear	Diagnoses of infection and hospitalisation after performing blood cultures	ED	5064	77 (68-83)	3217 (64)	365 (7)	Unclear	Mixed	Unclear	0.45
Iqbal et al., 2020 ²⁹	Spain	Retro-spective	Suspected infection	ED	1425	53 (19)	666 (47)	179 (13)	Clear	Mixed	Yes	0.51
Jimenez-Santos et al., 2014 ³⁰	Spain	Pro-spective	Oncology patients with fever	ED	152	63 (22)	71 (53)	22 (14)	Clear	Mixed	Yes	0.11, 0.2, 0.5
Julían-Jiménez et al., 2022 ³¹	Spain	Pro-spective	Clinical suspicion and diagnosis of infectious processes	ED	4436	67 (19)	2648 (60)	899 (20)	Clear	Mixed	Yes	0.1, 0.25, 0.51
Kaal et al., 2024 ³²	Netherlands	Pro-spective	Performing blood cultures	ED	2111	63 (NA)	1147 (54)	273 (13)	Clear	Mixed	Yes	0.1, 0.25, 0.5
Kim et al., 2015 ³³	Korea	Retro-spective	Testing of ANC, CRP, PCT and body temperature	ED	3305	Not specified	1855 (56)	564 (17)	Clear	Mixed	Unclear	0.1
Laukemann et al., 2015 ¹⁴	Switzerland	Pro-spective	Suspected infection	ED	1083	67 (53-78)	623 (58)	104 (10)	Clear	Mixed	Yes	0.1, 0.25, 0.5
Lawandi et al., 2023 ³⁴	USA	Retro-spective	Blood cultures and PCT testing within 24 h of admission	Mixed	74958	Not specifiedb	36589 (50)	9865 (13)	Clear	Mixed	Unclear	0.1, 0.25, 0.5
Lee et al., 2018 ³⁵	Zuid Korea	Retro-spective	Suspected acute cholangitis	ED	204	76 (17-102)	118 (58)	65 (32)	Unclear	Abdominal	Unclear	0.5

Study	Country	Type	Inclusion criteria	Setting (n)	Patients Age (y)	Male (%)	True positive BCs (%)	Contamination	Infection	Immuno-compromised	Antibiotic treatment	Cut-off values (ng/mL)	
Leroux et al., 2021 ³⁶	France	Retro-spective	PCT testing	ED	852	62 (23)	419 (49)	74 (9)	Clear	Mixed	Unclear	0.1, 0.25, 0.5	
Lin et al., 2017 ³⁷	Taiwan	Retro-spective	Performing blood cultures	ED	886	Not specified	197 (22)	Clear	Mixed	Unclear	Unclear	0.5	
Ljungstrom et al., 2017 ³⁸	Sweden	Pro-spective	Suspected community-onset sepsis	ED	1572	71 (58-81)	875 (56)	197 (13)	Unclear	Mixed	Unclear	0.1	
Loonen et al., 2014 ³⁹	Netherlands	Retro-spective	Clinically suspected infection with >2 SIRS criteria and performing of blood cultures	ED	118	BC-: 60, BC+: 69	74 (59)	20 (17)	Clear	Mixed	Unclear	2	
Marik et al., 2020 ⁴⁰	USA	Retro-spective	Testing of PCT, lactate, CBC with differential and blood cultures for suspected bacteraemia	Mixed	1767	61 (49-71)	NA (52)	384 (22)	Clear	Mixed	Unclear	0.5	
Naffaa 2014 ⁴¹	Israel	Pro-spective	Sepsis of any cause	Mixed	40	79 (68-84)	25 (63)	10 (25)	Clear	Mixed	No	1.35	
Nishino 2017 ⁴²	Japan	Pro-spective	Acute cholangitis	Mixed	62	75	46 (74)	29 (47)	Unclear	Abdominal	Unclear	3	
Oksuz et al., 2015 ⁴³	Turkey	Pro-spective	Febrile patients >37°C	Mixed	661	52 (18)	Not specified	77 (12)	Clear	Mixed	Unclear	0.1, 0.25, 0.5	
Oura et al., 2023 ⁴⁴	Japan	Retro-spective	Suspected acute cholangitis	Mixed	127	77 (71-85)	93 (67)c	71 (56)	Clear	Abdominal	Unclear	Yes	2.8

Study	Country	Type	Inclusion criteria	Setting	Patients (n)	Age (y)	Male (%)	True positive BCs (%)	Contamination	Infection	Immuno-compromised treatment	Antibiotic Cut-off values (ng/mL)
Palma et al., 2024 ⁴⁵	Spain	Retro-spective	Patients ≥75 y with clinically suspected infection and performing of blood cultures	ED	109	83 (6)	64 (59)	22 (20)	Clear	Mixed	Yes	Unclear 0.76
Romualdo et al., 2014 ⁴⁶	Spain	Pro-spective	At least two SIRS criteria and clinical suspicion of bacteraemia with performing blood cultures	ED	226	67 (26)	132 (58)	37 (16)	Clear	Mixed	Unclear	Yes 0.45
Roy et al., 2018 ⁴⁷	USA	Retro-spective	Suspected bacterial infection, PCT and blood cultures tested within 24 h of admission	Mixed	339	66 (17)	33 (50)	25 (7)	Clear	Mixed	Unclear	Unclear 0.5
Seo et al., 2015 ⁴⁸	Japan	Pro-spective	Admission due to infection	Mixed	78	79	40 (51)	29 (37)	Unclear	Mixed	No	Unclear 0.1, 0.25, 0.5
Takahashi et al., 2024 ⁴⁹	Japan	Retro-spective	Admission due to DKA or HHS	Mixed	608	58 (19)	329 (54)	70 (12)	Clear	Mixed	Unclear	Yes 0.1, 0.25, 0.5
Timbrook et al., 2023 ⁵⁰	USA	Retro-spective	Performing of blood cultures and PCT on day one of admission	Mixed	71105	68 (56-79)	35713 (50)	14846 (21)	Clear	Mixed	Yes	Unclear 0.5

Study	Country	Type	Inclusion criteria	Setting (n)	Patients Age (y)	Male (%)	True positive BCs (%)	Contamination	Infection	Immuno-compromised	Antibiotic treatment	Cut-off values (ng/mL)
Toreh et al., 2017 ⁵¹	Indonesia	Unclear	Suspected urosepsis with performing of blood cultures	Mixed 141	Not specified	Not specified	69 (49)	Clear	Urogenital	Unclear	Unclear	0.5
Uyar et al., 2023 ⁵²	Turkey	Pro-spective	Suspected sepsis	ED 47	BC-: 61. BC+: 62	31 (66)	20 (43)	Clear	Mixed	No	Yes	0.55
Wiwatcharagoses and Kingnakom 2016 ⁵³	Thailand	Pro-spective	Symptoms of systemic infections such as sepsis, severe sepsis, or septic shock	ED 110	52 (21)	59 (54)	23 (21)	Clear	Mixed	No	No	2
Xiao et al., 2024 ⁵⁴	China	Retro-spective	Admission due to sepsis or septic shock with testing blood cultures, PCT, presepsin and CRP	Mixed 577	70 (59-81)	340 (59)	170 (29)	Unclear	Mixed	Yes	Unclear	4.31
Yamaguchi et al., 2023 ⁵⁵	Japan	Retro-spective	Suspected acute cholangitis with performing of blood cultures	Mixed 69	BC-: 75, BC+: 82	44 (47)d	35 (51)	Clear	Abdominal	No	No	0.5
Youkhana et al., 2017 ⁵⁶	USA	Retro-spective	PCT and blood cultures performed within 24 h	Mixed 14387	Not specified	Not specified	1160 (8)	Clear	Mixed	Yes	Unclear	0.5

Study	Country	Type	Inclusion criteria	Setting	Patients (n)	Age (y)	Male (%)	True positive BCs (%)	Contamination	Infection	Immuno-compromised treatment	Antibiotic values (ng/mL)	Cut-off values (ng/mL)
Zhang et al., 2021 ⁵⁷	China	Pro-spective	At least two SIRS criteria with clinical suspicion of bacteraemia and performing blood cultures	Mixed	149	BC-: 59, BC+: 57	93 (62)	59 (40)	Clear	Mixed	No	Unclear	1.29
Zhang et al., 2023 ⁵⁸	China	Pro-spective	Suspected acute cholangitis and performing of prepsin, acylcarnitines and blood cultures	Mixed	280	74 (66-84)	166 (59)	92 (33)	Unclear	Abdominal	Unclear	Unclear	10.83

Type = retrospective versus prospective cohort study. Contamination: was there a clear definition of contaminated blood cultures? Immunocompromised: were immunocompromised patients included? Antibiotic treatment: inclusion of patients with recent (<7 d) antibiotic treatment. ANC, absolute neutrophil count; BC, blood culture; CBC, complete blood count; CRP, C-reactive protein; DKA, diabetic keto-acidosis; ED, emergency department; HHS, hyperglycemic hyperosmolar state; PCT, procalcitonin; SIRS, systemic inflammatory response syndrome.

a A total of 515 patients had a BC and PCT test; the mean age and gender were only given for the total number of patients: 898.

b Only age given for six subgroups, with medians ranging between 65 and 68 y.

c A total of 127 patients had a BC and PCT test; the mean age was only given for the total number of patients: 138.

d A total of 69 patients had a BC and PCT test; the mean age was only given for the total number of patients: 94.

Table 2. Risk of bias and applicability concerns per individual study as assessed by the QUADAS-2 tool

	Risk of bias				Applicability concerns		
	Patient selection	Index test	Reference standard	Flow and timing	Patient selection	Index test	Reference standard
Azjili et al., 2022 ²⁰	Low	Low	Low	Low	Low	Low	Low
Choe et al., 2016 ²¹	High	Low	High	High	Low	Low	High
Crotti et al., 2019 ²²	Unclear	Low	Unclear	Unclear	High	Low	Low
García de Guadiana-Romualdo et al., 2019 ²³	Low	High	Low	Low	Low	Low	Low
Julían-Jiménez et al., 2022 ²⁴	High	Low	Low	Low	Low	Low	Low
Harikrishna et al., 2020 ²⁵	Low	High	High	Low	Low	Low	Low
Hertz et al., 2024 ²⁶	Low	High	Low	High	Low	Low	Low
Hoenigl et al., 2014 ²⁷	High	Low	Low	Low	Low	Low	Low
Inoue et al., 2020 ²⁸	Unclear	High	Unclear	Unclear	Unclear	Unclear	Unclear
Iqbal et al., 2020 ²⁹	High	Low	Low	Low	Low	Low	Low
Jimenez-Santos et al., 2014 ³⁰	Low	Unclear	Low	Low	Low	Low	Low
Julían-Jiménez et al., 2022 ³¹	Low	Low	Low	High	Low	Low	Low
Kaal et al., 2024 ³²	Low	Low	Low	Low	Low	Low	Low
Kim et al., 2015 ³³	Low	Low	Low	Low	Low	Low	Low
Laukemann et al., 2015 ¹⁴	Low	Low	Low	Low	Low	Low	Low
Lawandi et al., 2023 ³⁴	High	Low	Low	High	Low	Low	Low
Lee et al., 2018 ³⁵	Low	High	High	Low	Low	Low	Low
Leroux et al., 2021 ³⁶	Low	Low	High	High	Low	Low	Low
Lin et al., 2017 ³⁷	Low	Low	Low	Low	Low	Low	Low
Ljungstrom et al., 2017 ³⁸	Low	Low	High	High	Low	Low	Low
Loonen et al., 2014 ³⁹	Low	Unclear	Low	High	Low	Low	Low

	Risk of bias				Applicability concerns		
	Patient selection	Index test	Reference standard	Flow and timing	Patient selection	Index test	Reference standard
Marik et al., 2020 ⁴⁰	Low	Low	Low	High	Low	Low	Low
Naffaa 2014 ⁴¹	Low	Low	High	Unclear	Low	Low	Low
Nishino 2017 ⁴²	Unclear	High	Unclear	Unclear	Low	Low	Unclear
Oksuz et al., 2015 ⁴³	Low	High	Low	Low	Low	Low	Unclear
Oura et al., 2023 ⁴⁴	Low	Low	Low	Low	Low	Low	Low
Palma et al., 2024 ⁴⁵	Low	High	Low	Low	Low	Low	Low
Romualdo et al., 2014 ⁴⁶	Low	High	Low	Low	Low	Low	Low
Roy et al., 2018 ⁴⁷	Unclear	Low	High	Unclear	Low	Low	Low
Seo et al., 2015 ⁴⁸	High	High	High	High	High	Low	High
Takahashi et al., 2024 ⁴⁹	Unclear	Low	Low	High	High	Low	Low
Timbrook et al., 2023 ⁵⁰	Low	Low	Low	High	Low	Low	Low
Toreh et al., 2017 ⁵¹	Unclear	Low	Unclear	Unclear	Low	Low	Unclear
Uyar et al., 2023 ⁵²	Low	High	Low	High	Low	Low	Low
Wiwatcharagoses and Kingnakom 2016 ⁵³	High	Low	High	High	Low	Low	Low
Xiao et al., 2024 ⁵⁴	High	High	High	Unclear	Low	Low	Low
Yamaguchi et al., 2023 ⁵⁵	High	Low	Low	High	Low	Low	Low
Youkhana et al., 2017 ⁵⁶	Unclear	Unclear	Low	High	Unclear	Unclear	Unclear
Zhang et al., 2023 ⁵⁸	High	High	High	Unclear	Low	Low	Low
Zhang et al., 2021 ⁵⁷	Low	High	Low	High	Low	Low	Low

Results of individual studies

Of all studies reporting on the lowest threshold (up to 0.15 ng/mL), sensitivity ranged from 28% to 99.9% with corresponding specificity of 15-80%. Fig. 2 shows the forest plot of all included studies. The corresponding 2 × 2 table can be found in the supplementary material. Of 40 studies, 30 reported an AUC of the ROC curve, ranging from 0.56 to 0.96, with substantial uncertainty per study.

Pooled results

The pooled sensitivity for the 0.10 ng/mL threshold was 93% (95% CI: 85-97%) with a specificity of 36% (95% CI: 26-47%) and an AUC of 0.68 (95% CI: 0.53-0.80). At the average bacteraemia prevalence of 16.3%, this would lead to a negative predictive value of 97.1%. The sensitivity prediction interval for a 0.10 ng/mL cut-off was 24-99.8% with specificity ranging between 17% and 94%. See Table 3 for the results for the other thresholds. The pooled AUC for all studies was 0.80 (95% CI: 0.76-0.83) (Fig. 3). The prediction interval for the AUC was 0.57-0.91.


Table 3. Pooled sensitivity and specificity with corresponding prediction intervals for all four analyses.

PCT threshold	Pooled sensitivity (95% CI)	Pooled specificity (95% CI)	Sensitivity prediction interval (%)	Specificity prediction interval (%)
0.10 ng/mL	92.8 (85.3-96.7)	35.7 (26.1-46.7)	24.0-99.8	17.0-94.0
0.25 ng/mL	85.1 (74.0-92.0)	55.4 (43.4-66.9)	20.0-99.0	8.0-88.0
0.50 ng/mL	78.6 (71.8-84.2)	68.9 (59.3-77.1)	27.0-97.0	3.0-87.0
Closest to 0.50 ng/mL	78.2 (72.8-82.7)	69.1 (62.0-75.7)	30.0-97.0	4.0-84.0

The first three analyses include only articles reporting on that threshold, whereas the fourth includes all articles using the threshold closest to a procalcitonin value of 0.50 ng/mL. The pooled sensitivity and specificity reflect the estimated average result. The prediction interval answers the question: 'If I would perform a new study, what will be my sensitivity and specificity with 95% certainty?

Subanalyses

In the subanalyses of all groups, pooled sensitivity was higher for an ED setting than a mixed setting (95% vs. 89% at a 0.10 ng/mL cut-off, prediction interval 42-99.8%). Studies using a clear definition of contaminated blood cultures also showed higher sensitivity than those without (80% vs. 69%, cut-off closest to 0.50 ng/mL). In the sensitivity analysis, we found higher pooled sensitivity for studies with low risk of bias, especially for the lower cut-offs (97% vs. 87% at a 0.10 ng/mL cut-off, specificity 34% vs. 37%, negative predictive value 98.3% vs. 93.6%, supplementary material). The prediction intervals for these low bias studies were 58-99.9% for sensitivity and 28-90% for specificity.



Publication bias

There was no indication of publication bias based on Deeks' funnel plot (p 0.59) (see supplementary material).




Fig. 3: Summary receiver operating characteristic (sROC) curve for the diagnostic accuracy of procalcitonin for bacteraemia, including the results at the reported threshold closest to 0.50 ng/mL. The small circle reflects the pooled sensitivity and specificity with the 95% CI shown as the larger solid circle, whereas the squares represent the results of the individual studies. The dotted line represents the prediction region, which illustrates the expected variability of sensitivity and specificity of a new study, accounting for between-study heterogeneity.

DISCUSSION

In this study, we updated a systematic review and meta-analysis of all studies published since the last meta-analysis regarding the diagnostic accuracy of PCT for CAB. We chose a new approach, focusing on the potential use of PCT to exclude CAB, to safely withhold unnecessary blood cultures. We found that with a low cut-off of 0.10 ng/mL, for a typical average study, the rate of missed bacteraemic episodes would be 7.2% (95% CI: 3.3-15%), while saving 36% (95% CI: 26-47%) of blood cultures. At the ED, the expected potential average savings are comparable (34% [95% CI: 25-44%]) with around 5% missed true positive blood cultures (95% CI: 2-11%).

Our findings are in line compared with one previous meta-analysis regarding a 0.50 ng/mL cut-off: a pooled sensitivity of 79% versus 76% and pooled specificity of

69% versus 69%, and an AUC of 0.81 versus 0.79¹². Another meta-analysis also showed a comparable AUC of 0.84 (0.75-0.90).¹¹

It is important to recognize the difference between the estimated pooled parameters with their CIs and the prediction intervals. The first estimates an average value. However, the prediction interval answers the question: 'If I would perform a new study, what will be my sensitivity and specificity with 95% certainty?'. This might be more relevant for clinical practice, and our results show that there is substantial between-study variation. The sensitivity prediction interval for a 0.10 ng/mL cut-off was very large (24-99.8%), as was the prediction interval for the AUC, ranging from 0.57 to 0.91. However, it is known that large heterogeneity leads to irreducible uncertainty, even when more studies would be performed.¹⁹ We did observe smaller intervals for studies with low risk of bias and ED studies. This underlines that the usability of PCT for excluding bacteraemia is highly dependent on the intended clinical setting.

On the basis of our findings, we believe that PCT can indeed be useful to rule out CAB in a typical setting, but we note that its value will largely depend on what risk of missing a true positive blood culture the treating clinician would find acceptable. It is known that clinicians require a high sensitivity, because this implies that we can safely exclude bacteraemia.⁵⁹ However, by decreasing the PCT threshold to increase sensitivity, specificity will inevitably decrease. This leads to less reduction of blood cultures, and will lead to more false-positive cultures. Some clinicians might argue that missing around 7% is unacceptable. The question remains whether this caution is justified because the vast majority of blood cultures do not impact treatment decisions; only 0.2-3% of all blood cultures taken at the ED do.^{60,61} Meanwhile, it is known that false-positive blood cultures are common (2-8%) and associated with negative patient outcomes such as increased length of stay, increased costs and more exposure to antibiotics.³⁻⁸ Therefore, we would argue that the local rate of false-positive cultures might be a good starting point when thinking about what rate of missed true positive blood cultures is acceptable.

In this meta-analysis, we choose to create four groups reflecting four thresholds. Each analysis was done using the bivariate model, including one threshold result per study. The Cochrane Handbook for diagnostic test accuracy reviews recommends using the hierarchical summary receiver operating characteristic (HSROC) model when studying multiple thresholds, because this model can include multiple thresholds per study in one analysis.¹⁸ On the basis of this model, one could estimate the pooled sensitivity and specificity for a 0.10 ng/mL cut-off. However, given our primary interest in the results of this lower threshold, we elected to analyse studies that reported results for this threshold, as opposed to estimating results primarily

based on data from higher thresholds. In addition, we have opted for a similar approach to that employed in the 2014 meta-analysis. This might help to increase the comparability of results.¹²

PCT is not only used as a diagnostic test, but is also extensively studied as a biomarker to guide antibiotic treatment. A meta-analysis showed that PCT-based algorithms reduced antibiotic exposure without an increase in mortality.⁶² Interestingly, although most of these PCT algorithms advice to withhold or to discontinue antibiotic treatment at a PCT level below 0.25 ng/mL, we showed that around 15% of true positive blood cultures did not have a PCT value over 0.25 ng/mL at presentation. This is a finding clinicians should be aware of when considering implementing such an algorithm.

It is impressive how many new articles in the past 10 years studied the diagnostic accuracy of PCT for CAB, whereas the results are comparable with previous meta-analysis. We believe that further studies regarding diagnostic accuracy of PCT for CAB will not lead to substantial reduction of uncertainty. Future studies should focus on either reporting even lower cut-offs of PCT that might lead to an acceptable trade-off between sensitivity and specificity, or on the interpretation of PCT in the clinical context. Prediction models that combine PCT with clinical predictors such as age and vital signs might help to safely withhold blood cultures.³² Finally, studies focusing on the cost-effectiveness of PCT testing for CAB will also help to determine its use in clinical practice.⁶³

We did not find an indication for publication bias using Deeks' funnel plot. However, detecting publication bias for diagnostic test accuracy studies is notoriously difficult, and cannot be excluded based on this test.¹⁸ However, we performed a very extensive search across multiple databases to retrieve potential studies, including studies in all languages, and reached out to authors in cases of missing data or unclear data. These efforts have likely decreased the risk of publication bias in this meta-analysis.

Notably, we found that studies using a clear definition of contaminated blood cultures found higher sensitivities. This makes sense, because false-positive blood cultures do not represent an inflammatory process and PCT values will likely not be elevated. If these cultures are analysed as true positives, this would falsely lead to a lower sensitivity. We would argue that when conducting research regarding blood cultures, defining a false-positive blood culture and analysing them as negative cultures is essential to produce reliable results. In this analysis, 15 of 40 included articles failed to do so, leading to possible biased results.

A strength of this study is the rigorous literature search, in which we independently screened 5450 articles in duplicate. We were able to include 40 articles representing a very large number of patients from a wide range of counties, making the results very robust and broadly applicable. A limitation of the study is that we choose to include the studies with high risk of bias in our main analysis. Studies with a low risk of bias had a higher pooled sensitivity of 97% (95% CI: 92-99%) with a pooled specificity of 34% (95% CI: 26-44%) (please see supplementary material). Our general conclusion might therefore be an underestimation of the true diagnostic accuracy of PCT for CAB. Furthermore, the included studies used a variety of PCT assays. Although all of the assays had a detection range that should be adequate for this study, it cannot be excluded that differences in sensitivity of the used assays will have influenced our results. However, we do not expect this to have led to clinically relevant differences. Finally, we choose the bivariate model in a selection of studies rather than using the hierarchical summary receiver operating characteristic model. This approach leads to a loss of available information in the analysis. However, as explained previously, we consider our approach more appropriate to answer our primary research question focusing on ruling out CAB.

In conclusion, using lower cut-off values of PCT to exclude CAB might be useful, depending on what the treating clinician considers to be an acceptable trade-off between sensitivity and specificity. Studies reporting on the combination of PCT with clinical parameters are needed to increase our understanding of the possible use of PCT to safely withhold unnecessary blood cultures.

CRedit authorship contribution statement

Anna G. Kaal: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Software, Validation, Visualization, Writing—original draft, Writing—review and editing. **Margot Nieberg:** Investigation, Validation, Writing—review and editing. **Koen Stegmeijer:** Investigation, Validation, Writing—review and editing. **Ewout W. Steyerberg:** Conceptualization, Methodology, Supervision, Writing—review and editing. **Cees van Nieuwkoop:** Conceptualization, Investigation, Methodology, Supervision, Validation, Writing—review and editing. N/A: Funding acquisition, Resources.

Transparency declaration

Potential conflict of interest

The authors declare that they have no conflicts of interest.

Financial report

No external funding was used to support this study.

Declaration of generative AI and AI-assisted technologies in the writing process

During the preparation of this work, the authors made use of ChatGPT for the sole purpose of enhancing its readability and linguistic quality. After using this tool, the authors have reviewed and edited the content as needed and take full responsibility for the content of the publication.

Acknowledgements

We would like to thank Pema Gurung for her help with setting up the search strategy.

SUPPLEMENTARY MATERIAL



REFERENCES

1. Jiménez-Aguilar P, López-Cortés LE, Rodríguez-Baño J. Impact of infectious diseases consultation on the outcome of patients with bacteraemia. *Ther Adv Infect Dis* 2019;6:2049936119893576.
2. Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. *Intensive Care Med* 2017;43:304-77.
3. Long B, Koyfman A. Best clinical practice: Blood culture utility in the emergency department. *J Emerg Med* 2016;51:529-39.
4. Coburn B, Morris AM, Tomlinson G, Detsky AS. Does this adult patient with suspected bacteremia require blood cultures? *JAMA* 2012;308:502-11.
5. Nannan Panday R. Evaluation of blood culture epidemiology and efficiency in a large European teaching hospital. *PLoS One* 2019;14:e0214052.
6. Dargère S, Cormier H, Verdon R. Contaminants in blood cultures: Importance, implications, interpretation and prevention. *Clin Microbiol Infect* 2018;24:964-9.
7. Dempsey C, Skoglund E, Muldrew KL, Garey KW. Economic health care costs of blood culture contamination: A systematic review. *Am J Infect Control* 2019;47:963-7.
8. Bates DW, Goldman L, Lee TH. Contaminant blood cultures and resource utilization. The true consequences of false-positive results. *JAMA* 1991;265:365-9.
9. Curren EJ, et al. Advancing diagnostic stewardship for healthcare associated Infections, antibiotic resistance, and sepsis. *Clin Infect Dis* 2022;74:723-8.
10. Morgan DJ, Malani PN, Diekema DJ. Diagnostic stewardship to prevent diagnostic error. *JAMA* 2023;329:1255-6.
11. Jones AE, Fiechtl JF, Brown MD, Ballew JJ, Kline JA. Procalcitonin test in the diagnosis of bacteremia: A meta-analysis. *Ann Emerg Med* 2007;50:34-41.
12. Hoeboer S, van der Geest PJ, Nieboer D, Groeneveld ABJ. The diagnostic accuracy of procalcitonin for bacteraemia: A systematic review and meta-analysis. *Clin Microbiol Infect* 2015;21:474-81.
13. van Nieuwkoop C, et al. Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: A prospective observational study. *Crit Care* 2010;14:R206.
14. Laukemann S, et al. Can we reduce negative blood cultures with clinical scores and blood markers? Results from an observational cohort study. *Medicine (Baltimore)* 2015;94:e2264.
15. Goodlet KJ, Cameron EA, Nailor MD. Low sensitivity of procalcitonin for bacteremia at an academic medical center: A cautionary tale for antimicrobial stewardship. *Open Forum Infect Dis* 2020;7:ofaa096.
16. Salameh J, et al. Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): Explanation, elaboration, and checklist *BMJ*. 2020;370:m2632.
17. Whiting PF, et al. QUADAS-2 Group. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med* 2011;155:529-36.
18. Deeks JJ, Bossuyt PM, Leeflang MM, Takwoingi Y. Cochrane handbook for systematic reviews of diagnostic test accuracy. The Cochrane Collaboration; 2023.

19. van Leeuwen FD, et al. Instability of the AUROC of clinical prediction models. *Stat Med* 2025;44:e70011.
20. Azijli K, et al. Optimal use of procalcitonin to rule out bacteremia in patients with possible viral infections. *J Am Coll Emerg Physicians Open* 2022;3(3):e12621.
21. Choe EA, et al. The prevalence and clinical significance of low procalcitonin levels among patients with severe sepsis or septic shock in the emergency department. *Shock* 2016;46:37-43.
22. Ciotti G, et al. Procalcitonin in the diagnostic work-up of febrile episodes in outpatients with hematologic malignancies. *Haematologica* 2019;104:150.
23. García de Guadiana-Romualdo L, et al. Prognostic value of procalcitonin and lipopolysaccharide binding protein in cancer patients with chemotherapy-associated febrile neutropenia presenting to an emergency department. *Biochem Med (Zagreb)* 2019;29:010702.
24. Julián-Jiménez A, et al. Utilidad del modelo 5MPB-Toledo para predecir bacteriemia en el paciente anciano. *Infectio* 2022;26:128-36.
25. Harikrishna J, et al. Serum procalcitonin as a biomarker of bloodstream infection & focal bacterial infection in febrile patients. *Indian J Med Res* 2020;151:342-9.
26. Hertz MA, et al. The diagnostic accuracy of procalcitonin, soluble urokinase-type plasminogen activator receptors, and C-reactive protein in diagnosing urinary tract infections in the emergency department. *J Clin Med* 2024;13:1776.
27. Hoenigl M, et al. Procalcitonin fails to predict bacteremia in SIRS patients: A cohort study. *Int J Clin Pract* 2014;68:1278-81.
28. Inoue H, et al. Procalcitonin (PCT) levels aids in distinguishing extended-spectrum beta-lactamases (ESBLs) producing Enterobacteriaceae bacteremia in emergency department. *J Infect Public Health* 2020;13:317-73.
29. Iqbal-Mirza SZ, et al. Factores predictores de bacteriemia en los pacientes atendidos en el Servicio de Urgencias por infección. *Rev Esp Quimioter* 2020;33:32-43.
30. Jimenez-Santos E, et al. Utilidad de la procalcitonina para predecir bacteriemia en pacientes oncológicos con fiebre. *Rev Lab Clín* 2014;7:127-33.
31. Julián-Jiménez A, et al. A bacteraemia risk prediction model: development and validation in an emergency medicine population. *Infection* 2022;50:203-21.
32. Kaal AG, et al. Procalcitonin for safe reduction of unnecessary blood cultures in the emergency department: Development and validation of a prediction model. *J Infect* 2024;89:106251.
33. Kim SY, et al. Procalcitonin in the assessment of bacteraemia in emergency department patients: Results of a large retrospective study. *Ann Clin Biochem* 2015;52(Pt 6):654-9.
34. Lawandi A, et al. Reliability of admission procalcitonin testing for capturing bacteremia across the sepsis spectrum. *Crit Care Med* 2023;51:1527-37.
35. Lee YS, et al. Procalcitonin as a decision-supporting marker of urgent biliary decompression in acute cholangitis. *Dig Dis Sci* 2018;63:2474-9.
36. Leroux P, et al. Clinical outcome predictive value of procalcitonin in patients suspected with infection in the emergency department. *Emerg Med Int* 2021;2021:2344212.

37. Lin CT, et al. Diagnostic value of serum procalcitonin, lactate, and high-sensitivity C-reactive protein for predicting bacteremia in adult patients in the emergency department. *PeerJ* 2017;5:e4094.
38. Ljungström L, et al. Diagnostic accuracy of procalcitonin, neutrophil-lymphocyte count ratio, C-reactive protein, and lactate in patients with suspected bacterial sepsis. *PLoS One* 2017;12:e0181704.
39. Loonen AJ, et al. Biomarkers and molecular analysis to improve bloodstream infection diagnostics in an emergency care unit. *PLoS One* 2014;9:e87315.
40. Marik PE, Stephenson E. The ability of procalcitonin, lactate, white blood cell count and neutrophil-lymphocyte count ratio to predict blood stream infection. Analysis of a large database. *J Crit Care* 2020;60:135-9.
41. Naffaa M, et al. Procalcitonin and interleukin 6 for predicting blood culture positivity in sepsis. *Am J Emerg Med* 2014;32:448-51.
42. Nishino T, et al. Evaluation of a proposed scoring system compared to procalcitonin levels and presepsin levels as predictors of a positive blood culture for bacteremia in acute cholangitis. *Gastroenterology* 2017;152:S500.
43. Oksuz L, et al. Procalcitonin and C-reactive protein in differentiating to contamination from bacteremia. *Braz J Microbiol* 2015;45:1415-21.
44. Oura H, et al. Diagnostic value of the serum lactate level as a predictor of bacteremia in patients with acute cholangitis. *J Hepatobiliary Pancreat Sci* 2023;30:1055-64.
45. Yañez Palma MC, et al. Utilidad de la región medial de la pro-adrenomodulina para la detección de bacteriemia verdadera en pacientes mayores atendidos en urgencias. *Rev Esp Quimioter* 2024;37:78-87.
46. Romualdo LG, et al. Diagnostic accuracy of presepsin (soluble CD14 subtype) for prediction of bacteremia in patients with systemic inflammatory response syndrome in the Emergency Department. *Clin Biochem* 2014;47:505-8.
47. Roy A, et al. Low procalcitonin can effectively rule out bacteremia. *Hosp Med* 2018; April 8-11;13. Orlando, FL. Abstract number 342.
48. Seo K, et al. Characteristics of serum endocan levels in infection. *PLoS One* 2015;10:e0123358.
49. Takahashi K, et al. Epidemiology, microbiology, and diagnosis of infection in diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome. *Diabetes Res Clin Pract* 2024;212:111713.
50. Timbrook TT, et al. Procalcitonin and risk prediction for diagnosing bacteremia in hospitalized patients: A retrospective, national observational study. *Diagnostics (Basel)* 2023;13:3174.
51. Toreh C, et al. Procalcitonin levels predict bacteremia in patients with urosepsis. *Int J Urol* 2017;24:87.
52. Yurttutan Uyar N, et al. Sepsis biomarkers for early diagnosis of bacteremia in emergency department. *J Infect Dev Ctries* 2023;17:832-9.
53. Wiwatcharagoses K, Kingnakom A. Procalcitonin under Investigation as a means of detecting severe sepsis, septic shock and bacteremia at emergency department, Rajavithi hospital. *J Med Assoc Thai* 2016;99(Suppl 2):S63-8.

54. Xiao H, et al. Comparison among presepsin, procalcitonin, and C-Reactive protein in predicting blood culture positivity and pathogen in sepsis patients. *Shock* 2024;1(61):387-94.
55. Yamaguchi A, et al. Proportion of neutrophils in white blood cells as a useful marker for predicting bacteremic acute cholangitis. *Intern Med* 2023;62:2795-802.
56. Youkhana K, et al. The clinical utility of serum procalcitonin as a diagnostic assay for predicting bacteremia in patients with sepsis. *Chest* 2017;152(Suppl):A347.
57. Zhang CY, et al. Clinical value of alkaline phosphatase on the surface membrane of neutrophils for prediction of bacteremia in patients with systemic inflammatory response syndrome. *Diagn Microbiol Infect Dis* 2021;100:114105.
58. Zhang HY, et al. Predictive value of presepsin and acylcarnitines for severity and biliary drainage in acute cholangitis. *World J Gastroenterol* 2023;29:2502-14.
59. Lautenbach E, Localio R, Nachamkin I. Clinicians required very high sensitivity of a bacteremia prediction rule. *J Clin Epidemiol* 2004;57:1104-6.
60. Howie N, Gerstenmaier JF, Munro PT. Do peripheral blood cultures taken in the emergency department influence clinical management? *Emerg Med J* 2007;24:213-4.
61. Mountain D, Bailey PM, O'Brien D, Jelinek GA. Blood cultures ordered in the adult emergency department are rarely useful. *Eur J Emerg Med* 2006;13:76-9.
62. Meier MA, et al. Procalcitonin-guided antibiotic treatment in patients with positive blood cultures: A patient-level meta-analysis of randomized trials. *Clin Infect Dis* 2019;69:388-96.
63. Schuetz P, et al. Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective. *Clin Chem Lab Med* 2015;53:583-92.

